Screener
Supernus Pharmaceuticals SUPN Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 423,920 | 390,934 |
| Commitments and contingencies (Note 17) | ||
| Stockholders' equity | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 58,039,721 and 57,457,462 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 58 | 57 |
| Additional paid-in capital | 561,419 | 543,825 |
| Accumulated other comprehensive loss, net of tax | (255) | (44) |
| Retained earnings | 515,583 | 517,876 |
| Total stockholders' equity | 1,076,805 | 1,061,714 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's common stock, par value (in dollars per share)?
- Supernus Pharmaceuticals (SUPN) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Supernus Pharmaceuticals's common stock, par value (in dollars per share) changed year-over-year?
- Supernus Pharmaceuticals's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Supernus Pharmaceuticals's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Supernus Pharmaceuticals's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude